6-K
Materialise NV (MTLS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission File Number: 001-36515
Materialise NV
Technologielaan 15
3001 Leuven
Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
EXHIBIT INDEX
| Exhibit | Description |
|---|---|
| 99.1 | Press Release dated February 20, 2025 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MATERIALISE NV | |
|---|---|
| By: | /s/ Brigitte de Vet-Veithen |
| Name: | Brigitte de Vet-Veithen |
| De Vet Management BV | |
| Title: | Chief Executive Officer |
Date: February 20, 2025
Exhibit 99.1
Materialise Reports Fourth Quarter and Full Year 2024 Results
LEUVEN, Belgium--(BUSINESS WIRE)— February 20, 2025 -- Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing and medical software solutions and of sophisticated 3D printing services, today announced its financial results for the fourth quarter and full year ended December 31, 2024.
Highlights – Fourth Quarter 2024
| · | Total revenue increased 0.6% to 65,680 kEUR for<br>the fourth quarter of 2024 from 65,295 kEUR for the corresponding 2023 period boosted by 14.3% growth in our Materialise Medical segment. |
|---|---|
| · | Total deferred revenues from software maintenance<br>and license fees increased by 5,878 kEUR this quarter to 46,948 kEUR. |
| · | Adjusted EBITDA amounted to 4,306 kEUR for the<br>fourth quarter of 2024 compared to 8,474 kEUR for the corresponding 2023 period. Adjusted EBIT amounted to (1,195) kEUR for the fourth<br>quarter of 2024 compared to 3,154 kEUR for the 2023 period. |
| · | Net result for the fourth quarter of 2024 was<br>2,907 kEUR, or 0.05 EUR per diluted share, compared to a net result of (539) kEUR, or (0.01) EUR per diluted share for the corresponding<br>2023 period. |
Highlights – Full Year 2024
| · | Total revenue increased 4.2% to 266,765 kEUR<br>for 2024 from 256,127 kEUR for 2023 boosted by 14.8% growth in our Materialise Medical segment. |
|---|---|
| · | Gross profit as a percentage of revenue for 2024<br>remained stable at 56.5%, compared to 56.7% for 2023. |
| · | Adjusted EBITDA was 31,484 kEUR for 2024 compared<br>to 31,397 kEUR for 2023. Adjusted EBIT decreased slightly to 9,741 kEUR for 2024 from 9,886 kEUR for 2023. |
| · | Net profit for 2024 was 13,406 kEUR, or 0.23<br>EUR per diluted share, compared to a net profit of 6,695 kEUR, or 0.11 EUR per diluted share, for 2023. |
| · | Total cash reserves amounted to 102,304 kEUR<br>at the end of 2024. |
CEO Brigitte de Vet-Veithen commented, “Inthe final quarter of 2024 our Materialise Medical segment continued on its growth path, again posting record-high revenues. Atthe same time, global macro-economic headwinds persisted particularly in the European industrial sector, impacting Materialise Manufacturingsegment’s performance. Our Materialise Software segment continued to make good progress in its conversion to a recurring revenuebusiness model and delivered results in line with our expectations. Continued high R&D expenditures especially in our MaterialiseMedical and Software segments combined with integration and restructuring costs in our Materialise Manufacturing segment and in our corporatesupport departments impacted Adjusted EBIT in the fourth quarter of 2024. Over the full year 2024 we delivered a positive net result of0.23 EUR per diluted share and increased our operational cash flow by 56% to 31.5 million EUR.”
Fourth Quarter 2024 Results
Total revenue for the fourth quarter of 2024 increased 0.6% to 65,680 kEUR from 65,295 kEUR for the fourth quarter of 2023. Adjusted EBITDA decreased to 4,306 kEUR for the fourth quarter of 2024 from 8,474 kEUR for the 2023 period. Adjusted EBIT amounted to (1,195) kEUR, compared to 3,154 kEUR for the same period in 2023.
Revenue from our Materialise Medical segment increased 14.3% to 31,837 kEUR for the fourth quarter of 2024, compared to 27,848 kEUR for the same period in 2023. Adjusted EBITDA for the segment was 9,547 kEUR compared to 9,365 kEUR, while the Adjusted EBITDA margin for the segment was 30.0%, compared to 33.6% for the prior-year period.
Revenue from our Materialise Software segment decreased 1.1% to 11,124 kEUR from 11,250 kEUR for the same quarter last year. Adjusted EBITDA for the segment amounted to 1,123 kEUR compared to 1,259 kEUR, while the Adjusted EBITDA margin for the segment was 10.1%, compared to 11.2% for the prior-year period.
Revenue from our Materialise Manufacturing segment decreased 13.3% to 22,719 kEUR from 26,198 kEUR for the fourth quarter of 2023. Adjusted EBITDA for the segment decreased to (2,989) kEUR compared to 557 kEUR, while the Adjusted EBITDA margin for the segment was (13.2)%, compared to 2.1% for the prior-year period.
Gross profit decreased 3.2% to 36,365 kEUR for the fourth quarter of 2024 from 37,548 kEUR for the same period last year. Gross profit as a percentage of revenue was 55.4%, compared to 57.5%.
Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 10.2% to 38,990 kEUR for the fourth quarter of 2024 from 35,375 kEUR for the fourth quarter of 2023 mainly driven by a 19.6% increase in R&D spend.
Net other operating income was 1,357 kEUR compared to (3,287) kEUR for the fourth quarter of 2023, whereas the last quarter of 2023 included non-recurring charges from the impairment of goodwill, tangible and intangible assets of 4,228 kEUR.
The operating result was (1,268) kEUR, compared to (1,113) kEUR for the fourth quarter of 2023.
Net financial result for the fourth quarter of 2024 was 3,301 kEUR, compared to (234) kEUR for the corresponding period of 2023 reflecting favorable effects from exchange rate fluctuations.
The fourth quarter of 2024 contained net tax income of 874 kEUR, compared to net tax income of 809 kEUR for the fourth quarter of 2023.
As a result of the above, net profit for the fourth quarter of 2024 was 2,907 kEUR, compared to a net loss of (539) kEUR for the same period in 2023. Total comprehensive income for the fourth quarter of 2024 was 1,432 kEUR, compared to (112) kEUR for the 2023 period.
Cash flow from operating activities for the fourth quarter of the year 2024 was 6,218 kEUR, compared to 195 kEUR for the same period in 2023. Total capital expenditures for the fourth quarter of the year 2024 amounted to 7,760 kEUR.
Full Year 2024 Results
Total revenues for the year ended December 31, 2024 increased 4.2% to 266,765 kEUR from 256,127 kEUR for the year ended December 31, 2023. Adjusted EBITDA for 2024 amounted to 31,484 kEUR compared to 31,397 kEUR for 2023. The Adjusted EBITDA margin was 11.8% in 2024, compared to 12.3% in 2023. Adjusted EBIT for 2024 amounted to 9,741 kEUR compared to 9,886 kEUR for 2023. The Adjusted EBIT margin for 2024 was 3.7%, compared to 3.9% for 2023.
Revenues from our Materialise Medical segment grew by 14.8% for the year ended December 31, 2024 to 116,358 kEUR from 101,376 kEUR for the year ended December 31, 2023. The segment’s Adjusted EBITDA increased to 35,562 kEUR from 26,544 kEUR. The segment’s Adjusted EBITDA margin was 30.6% in 2024, compared to 26.2% in 2023.
Revenues from our Materialise Software segment decreased 1.2% to 43,899 kEUR for the year ended December 31, 2024 compared to 44,442 kEUR for the year ended December 31, 2023. The segment’s Adjusted EBITDA decreased to 5,562 kEUR from 7,450 kEUR in 2023. The segment’s Adjusted EBITDA margin was 12.7% in 2024, compared to 16.8% in 2023.
Revenues from our Materialise Manufacturing segment decreased 3.4% to 106,508 kEUR for the year ended December 31, 2024 from 110,310 kEUR for the year ended December 31, 2023. The segment’s Adjusted EBITDA amounted to 1,660 kEUR compared to 7,537 kEUR. The segment’s Adjusted EBITDA margin was 1.6% in 2024, compared to 6.8% in 2023.
Gross profit increased 3.9% to 150,826 kEUR from 145,131 kEUR last year. Gross profit as a percentage of revenue was 56.5%, compared to 56.7% in 2023.
Net other operating income was 4,223 kEUR compared to (6,524) kEUR for 2023, whereas 2023 included non-recurring charges from the impairment of goodwill, tangible and intangible assets of 4,228 kEUR.
Operating result amounted to 9,432 kEUR for the year ended December 31, 2024 compared to 5,619 kEUR in the prior year.
Net financial result amounted to 4,707 kEUR, compared to net financial result of 1,154 kEUR for the year ended December 31, 2023. Income taxes amounted to (733) kEUR compared to (78) kEUR for the year ended December 31, 2023. As a result, net profit was 13,406 kEUR for 2024 compared to a net profit of 6,695 kEUR in 2023.
At December 31, 2024, we had cash and equivalents of 102,304 kEUR compared to 127,573 kEUR at December 31, 2023. Gross debt reduced to 41,284 kEUR (of which 12,997 kEUR was short term), compared to 64,398 kEUR at December 31, 2023.
Cash flow from operating activities for the year ended December 31, 2024 was 31,456 kEUR compared to 20,157 kEUR in the year ended December 31, 2023. Total capital expenditures for the year ended December 31, 2024 amounted to 26,377 kEUR.
Net shareholders’ equity at December 31, 2024 was 248,492 kEUR compared to 236,594 kEUR at December 31, 2023, representing an increase of 5.0%.
2025 Guidance
Mrs. de Vet-Veithen concluded, “Forcalendar year 2025, we expect our three reporting segments to evolve at a different pace. We anticipate the strongest revenue growth tocome from our Materialise Medical segment. Materialise Software will continue its transition towards a cloud-based subscription businessmodel, which will impact its revenue growth potential. Furthermore, we anticipate the difficult macroeconomic environment will persistthroughout 2025, specifically in the European industrial sector, which will impact the performance of our Materialise Manufacturing segment.On a consolidated level we expect our full year revenues for 2025 to grow to a range of 270.000 to 285.000 kEUR. We will continue investingin our Materialise Medical and Software segments while keeping a strong focus on cost control and optimization in particular in our MaterialiseManufacturing segment and in our corporate support departments. For calendar year 2025, we anticipate our Adjusted EBIT will reach 6.000to 10.000 kEUR reflecting also increased depreciation charges.”
Non-IFRS Measures
Materialise uses EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA as supplemental financial measures of its financial performance. EBIT is calculated as net profit plus income taxes, financial expenses (less financial income) and shares of profit or loss in a joint venture. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBIT and Adjusted EBITDA are determined by adding share-based compensation expenses, acquisition-related expenses of business combinations, impairments and revaluation of fair value due to business combinations to EBIT and EBITDA, respectively. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of financing decisions and, in the case of EBITDA and Adjusted EBITDA, long term investment, rather than the performance of the company’s day-to-day operations. The company also uses segment Adjusted EBITDA to evaluate the performance of its three business segments. As compared to net profit, these measures are limited in that they do not reflect the cash requirements necessary to service interest or principal payments on the company’s indebtedness and, in the case of EBITDA and Adjusted EBITDA, these measures are further limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the changes associated with impairments. Management evaluates such items through other financial measures such as financial expenses, capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBIT, EBITDA, Adjusted EBIT and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.039, the reference rate of the European Central Bank on December 31, 2024.
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the fourth quarter of 2024 and other matters on Thursday, February 20, 2025, at 8:30 a.m. ET/2:30 p.m. CET. Company participants on the call will include Brigitte de Vet-Veithen, Chief Executive Officer; and Koen Berges, Chief Financial Officer. A question-and-answer session will follow management’s remarks. To access the call by phone, please click the link below at least 15 minutes prior to the scheduled start time and you will be provided with dial-in details. Participants can choose to dial in or receive a call to connect to Materialise’s conference call.
| · | https://register.vevent.com/register/BI291a6f2c7454403ba50a5ec3e4455faa |
|---|
The conference call will also be broadcast live over the internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. A webcast of the conference call will be archived on the company's website for one year.
About Materialise
Materialise incorporates over 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest and most complete 3D printing facilities in the world. For additional information, please visit: www.materialise.com.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our estimates for the current fiscal year’s revenue and Adjusted EBIT, our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the current armed geopolitical conflicts around the world and governmental responses thereto, inflation, increased labor, energy and materials costs), policy changes resulting from the U.S. presidential administration, changes in tariffs and trade restrictions, and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from our expectations, including risk factors described in the company's most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. There are a number of risks and uncertainties that could cause the company's actual results to differ materially from the forward-looking statements contained in this press release.
The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
Consolidated income statements (Unaudited)
| for the three months ended December 31, | for the twelve months ended December 31, | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| In '000 | 2024 | 2024 | 2023 | 2024 | 2023 | |||||
| U.S. | ||||||||||
| Revenue | 68,235 | 65,680 | 65,295 | 266,765 | 256,127 | |||||
| Cost of Sales | (30,455 | ) | (29,315 | ) | (27,747 | ) | (115,940 | ) | (110,996 | ) |
| Gross Profit | 37,780 | 36,365 | 37,548 | 150,826 | 145,131 | |||||
| Gross profit as % of revenue | 55.4 | % | 55.4 | % | 57.5 | % | 56.5 | % | 56.7 | % |
| Research and development expenses | (12,569 | ) | (12,099 | ) | (10,116 | ) | (44,400 | ) | (38,098 | ) |
| Sales and marketing expenses | (17,131 | ) | (16,490 | ) | (15,403 | ) | (61,620 | ) | (57,822 | ) |
| General and administrative expenses | (10,806 | ) | (10,402 | ) | (9,855 | ) | (39,597 | ) | (37,068 | ) |
| Net other operating income (expenses) | 1,410 | 1,357 | (3,287 | ) | 4,223 | (6,524 | ) | |||
| Operating (loss) profit | (1,316 | ) | (1,268 | ) | (1,113 | ) | 9,432 | 5,619 | ||
| Financial expenses | (451 | ) | (434 | ) | (266 | ) | (4,516 | ) | (3,865 | ) |
| Financial income | 3,880 | 3,735 | 32 | 9,224 | 5,019 | |||||
| (Loss) profit before taxes | 2,113 | 2,033 | (1,348 | ) | 14,139 | 6,772 | ||||
| Income Taxes | 908 | 874 | 809 | (733 | ) | (78 | ) | |||
| Net (loss) profit for the period | 3,021 | 2,907 | (539 | ) | 13,406 | 6,695 | ||||
| Net (loss) profit attributable to: | ||||||||||
| The owners of the parent | 3,030 | 2,917 | (529 | ) | 13,436 | 6,722 | ||||
| Non-controlling interest | (10 | ) | (10 | ) | (10 | ) | (30 | ) | (27 | ) |
| Earning per share attributable to owners of the parent | ||||||||||
| Basic | 0.05 | 0.05 | (0.01 | ) | 0.23 | 0.11 | ||||
| Diluted | 0.05 | 0.05 | (0.01 | ) | 0.23 | 0.11 | ||||
| Weighted average basic shares outstanding | 59,067 | 59,067 | 59,067 | 59,067 | 59,067 | |||||
| Weighted average diluted shares outstanding | 59,148 | 59,148 | 59,067 | 59,105 | 59,085 |
All values are in US Dollars.
Consolidated statements of comprehensive income (Unaudited)
| for the three months ended December 31, | for the twelve months ended December 31, | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| In 000€ | 2024 | 2024 | 2023 | 2024 | 2023 | |||||
| U.S. | ||||||||||
| Net profit (loss) for the period | 3,021 | 2,907 | (539 | ) | 13,406 | 6,695 | ||||
| Other comprehensive income | ||||||||||
| Recycling | ||||||||||
| Exchange difference on translation of foreign operations | (1,536 | ) | (1,478 | ) | 759 | (1,795 | ) | 1,255 | ||
| Non-recycling | ||||||||||
| Fair value adjustments through OCI - Equity instruments | 3 | 3 | (331 | ) | 3 | (331 | ) | |||
| Other comprehensive income (loss), net of taxes | (1,532 | ) | (1,475 | ) | 428 | (1,792 | ) | 924 | ||
| Total comprehensive income (loss) for the year, net of taxes | 1,487 | 1,432 | (112 | ) | 11,615 | 7,619 | ||||
| Total comprehensive income (loss) attributable to: | ||||||||||
| The owners of the parent | 1,501 | 1,445 | (102 | ) | 11,647 | 7,644 | ||||
| Non-controlling interests | (13 | ) | (13 | ) | (10 | ) | (33 | ) | (25 | ) |
All values are in US Dollars.
Consolidated statement of financial position (Unaudited)
| As of<br> December 31, | As of<br> December 31, | |||
|---|---|---|---|---|
| In 000€ | 2024 | 2023 | ||
| Assets | ||||
| Non-current assets | ||||
| Goodwill | 43,391 | 43,158 | ||
| Intangible assets | 29,973 | 31,464 | ||
| Property, plant & equipment | 111,331 | 95,400 | ||
| Right-of-Use assets | 7,719 | 8,102 | ||
| Deferred tax assets | 3,523 | 2,797 | ||
| Investments in convertible loans | 3,994 | 3,744 | ||
| Other non-current assets | 5,892 | 5,501 | ||
| Total non-current assets | 205,823 | 190,166 | ||
| Current assets | ||||
| Inventories | 16,992 | 17,034 | ||
| Trade receivables | 53,052 | 52,698 | ||
| Other current assets | 18,165 | 9,161 | ||
| Cash and cash equivalents | 102,304 | 127,573 | ||
| Total current assets | 190,513 | 206,465 | ||
| Total assets | 396,336 | 396,630 | ||
| As of<br> December 31, | As of<br> December 31, | |||
| --- | --- | --- | --- | --- |
| In 000€ | 2024 | 2023 | ||
| Equity and liabilities | ||||
| Equity | ||||
| Share capital | 4,487 | 4,487 | ||
| Share premium | 234,228 | 233,942 | ||
| Retained earnings and other reserves | 9,863 | (1,783 | ) | |
| Equity attributable to the owners of the parent | 248,578 | 236,646 | ||
| Non-controlling interest | (86 | ) | (53 | ) |
| Total equity | 248,492 | 236,594 | ||
| Non-current liabilities | ||||
| Loans & borrowings | 23,175 | 33,582 | ||
| Lease liabilities | 5,112 | 5,333 | ||
| Deferred tax liabilities | 3,202 | 3,725 | ||
| Deferred income | 13,268 | 10,701 | ||
| Other non-current liabilities | 909 | 1,745 | ||
| Total non-current liabilities | 45,666 | 55,086 | ||
| Current liabilities | ||||
| Loans & borrowings | 10,383 | 22,873 | ||
| Lease liabilities | 2,614 | 2,610 | ||
| Trade payables | 23,348 | 21,196 | ||
| Tax payables | 1,432 | 1,777 | ||
| Deferred income | 45,998 | 40,791 | ||
| Other current liabilities | 18,403 | 15,703 | ||
| Total current liabilities | 102,178 | 104,950 | ||
| Total equity and liabilities | 396,336 | 396,630 |
Consolidated statement of cash flows (Unaudited)
| for the twelve months ended <br><br>December 31, | ||||
|---|---|---|---|---|
| In 000€ | 2024 | 2023 | ||
| Operating activities | ||||
| Net (loss) profit for the period | 13,406 | 6,695 | ||
| Non-cash and operational adjustments | 18,655 | 24,571 | ||
| Depreciation of property plant & equipment | 15,372 | 15,065 | ||
| Amortization of intangible assets | 6,435 | 6,504 | ||
| Impairment of goodwill and intangible assets | - | 4,228 | ||
| (Gain) on bargain purchase | (23 | ) | ||
| Share-based payment expense | 285 | 39 | ||
| Loss (gain) on disposal of intangible assets and property, plant & equipment | (312 | ) | (415 | ) |
| Government grants | (57 | ) | ||
| Movement in provisions | 539 | (181 | ) | |
| Movement reserve for bad debt and slow moving inventory | 236 | 499 | ||
| Financial income | (9,122 | ) | (5,033 | ) |
| Financial expense | 4,559 | 3,886 | ||
| Impact of foreign currencies | 29 | (94 | ) | |
| (Deferred) income taxes | 714 | 73 | ||
| Working capital adjustments | (1,418 | ) | (12,576 | ) |
| Decrease (increase) in trade receivables and other receivables | (1,037 | ) | (3,335 | ) |
| Decrease (increase) in inventories and contracts in progress | (372 | ) | (806 | ) |
| Increase (decrease) in deferred revenue | 1,270 | 525 | ||
| Increase (decrease) in trade payables and other payables | (1,279 | ) | (8,961 | ) |
| Income tax paid & Interest received | 813 | 1,469 | ||
| Net cash flow from operating activities | 31,456 | 20,157 | ||
| for the twelve months ended<br> December 31, | ||||
| --- | --- | --- | --- | --- |
| In 000€ | 2024 | 2023 | ||
| Investing activities | ||||
| Purchase of property, plant & equipment | (24,649 | ) | (9,235 | ) |
| Purchase of intangible assets | (1,728 | ) | (2,525 | ) |
| Proceeds from the sale of property, plant & equipment & intangible assets (net) | 458 | 723 | ||
| Acquisition of subsidiary (net of cash) | (2,670 | ) | - | |
| Net cash flow used in investing activities | (28,588 | ) | (11,037 | ) |
| Financing activities | ||||
| Repayment of loans & borrowings | (23,267 | ) | (16,723 | ) |
| Repayment of leases | (3,122 | ) | (3,549 | ) |
| Capital increase | - | - | ||
| Interest paid | (1,337 | ) | (1,750 | ) |
| Other financial income (expense) | 81 | (346 | ) | |
| Net cash flow from (used in) financing activities | (27,644 | ) | (22,368 | ) |
| Net increase/(decrease) of cash & cash equivalents | (24,776 | ) | (13,248 | ) |
| Cash & Cash equivalents at the beginning of the year | 127,573 | 140,867 | ||
| Exchange rate differences on cash & cash equivalents | (492 | ) | (46 | ) |
| Cash & cash equivalents at end of the period | 102,304 | 127,573 |
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)
| for the three months ended<br> December 31, | for the twelve months ended<br> December 31, | |||||||
|---|---|---|---|---|---|---|---|---|
| In 000€ | 2024 | 2023 | 2024 | 2023 | ||||
| Net profit (loss) for the period | 2,907 | (539 | ) | 13,406 | 6,695 | |||
| Income taxes | (874 | ) | (809 | ) | 733 | 78 | ||
| Financial expenses | 434 | 266 | 4,516 | 3,865 | ||||
| Financial income | (3,735 | ) | (32 | ) | (9,224 | ) | (5,019 | ) |
| Depreciation and amortization | 5,501 | 5,320 | 21,742 | 21,511 | ||||
| EBITDA | 4,234 | 4,207 | 31,175 | 27,130 | ||||
| Share-based compensation expense (1) | 72 | 39 | 285 | 39 | ||||
| Impairments (2) | - | 4,228 | - | 4,228 | ||||
| Acquisition-related expenses of business combinations (3) | - | - | 24 | - | ||||
| Adjusted EBITDA | 4,306 | 8,474 | 31,484 | 31,397 |
(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.
(2) Impairments represent the impairment of goodwill and intangible assets of Materialise Motion (3,572 kEUR) and the impairment of tangible and intangible assets of Engimplan (656 kEUR).
(3) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.
Reconciliation of Net Profit (Loss) to EBIT and Adjusted EBIT (Unaudited)
| for the three months ended<br><br>December 31, | for the twelve months ended<br><br> December 31, | |||||||
|---|---|---|---|---|---|---|---|---|
| In 000€ | 2024 | 2023 | 2024 | 2023 | ||||
| Net profit (loss) for the period | 2,907 | (539 | ) | 13,406 | 6,695 | |||
| Income taxes | (874 | ) | (809 | ) | 733 | 78 | ||
| Financial expenses | 434 | 266 | 4,516 | 3,865 | ||||
| Financial income | (3,735 | ) | (32 | ) | (9,224 | ) | (5,019 | ) |
| EBIT | (1,268 | ) | (1,113 | ) | 9,432 | 5,619 | ||
| Share-based compensation expense (1) | 72 | 39 | 285 | 39 | ||||
| Impairments (2) | - | 4,228 | - | 4,228 | ||||
| Acquisition-related expenses of business combinations (3) | - | - | 24 | - | ||||
| Adjusted EBIT | (1,195 | ) | 3,154 | 9,741 | 9,886 |
(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.
(2) Impairments represent the impairment of goodwill and intangible assets of Materialise Motion (3,572 kEUR) and the impairment of tangible and intangible assets of Engimplan (656 kEUR).
(3) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.
Segment P&L (Unaudited)
| In 000€ | Materialise<br> Medical | Materialise<br> Software | Materialise<br> Manufacturing | Total<br> segments | Unallocated<br> (1) | Consolidated | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| For the three months ended December 31, 2024 | ||||||||||||
| Revenues | 31,837 | 11,124 | 22,719 | 65,680 | 0 | 65,680 | ||||||
| Segment (adj) EBITDA | 9,547 | 1,123 | (2,989 | ) | 7,681 | (3,375 | ) | 4,306 | ||||
| Segment (adj) EBITDA % | 30.0 | % | 10.1 | % | -13.2 | % | 11.7 | % | 6.6 | % | ||
| For the three months ended December 31, 2023 | ||||||||||||
| Revenues | 27,848 | 11,250 | 26,198 | 65,295 | 0 | 65,295 | ||||||
| Segment (adj) EBITDA | 9,365 | 1,259 | 557 | 11,181 | (2,708 | ) | 8,474 | |||||
| Segment (adj) EBITDA % | 33.6 | % | 11.2 | % | 2.1 | % | 17.1 | % | 13.0 | % | ||
| In 000€ | Materialise<br> Medical | Materialise<br> Software | Materialise<br> Manufacturing | Total<br> segments | Unallocated<br> (1) | Consolidated | ||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| For the twelve months ended December 31, 2024 | ||||||||||||
| Revenues | 116,358 | 43,899 | 106,508 | 266,765 | 0 | 266,765 | ||||||
| Segment (adj) EBITDA | 35,562 | 5,562 | 1,660 | 42,784 | (11,300 | ) | 31,484 | |||||
| Segment (adj) EBITDA % | 30.6 | % | 12.7 | % | 1.6 | % | 16.0 | % | 11.8 | % | ||
| For the twelve months ended December 31, 2023 | ||||||||||||
| Revenues | 101,376 | 44,442 | 110,310 | 256,127 | 0 | 256,127 | ||||||
| Segment (adj) EBITDA | 26,544 | 7,450 | 7,537 | 41,530 | (10,133 | ) | 31,397 | |||||
| Segment (adj) EBITDA % | 26.2 | % | 16.8 | % | 6.8 | % | 16.2 | % | 12.3 | % |
(1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA.
Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)
| for the three months ended<br> December 31, | for the twelve months ended<br> December 31, | |||||||
|---|---|---|---|---|---|---|---|---|
| In 000€ | 2024 | 2023 | 2024 | 2023 | ||||
| Net profit (loss) for the period | 2,907 | (539 | ) | 13,406 | 6,695 | |||
| Income taxes | (874 | ) | (809 | ) | 733 | 78 | ||
| Financial cost | 434 | 266 | 4,516 | 3,865 | ||||
| Financial income | (3,735 | ) | (32 | ) | (9,224 | ) | (5,019 | ) |
| Operating (loss) profit | (1,268 | ) | (1,113 | ) | 9,432 | 5,619 | ||
| Depreciation and amortization | 5,501 | 5,320 | 21,742 | 21,511 | ||||
| Corporate research and development | 1,006 | 721 | 3,681 | 2,785 | ||||
| Corporate headquarter costs | 2,717 | 2,869 | 10,254 | 10,464 | ||||
| Other operating income (expense) | (276 | ) | (844 | ) | (2,350 | ) | (3,077 | ) |
| Impairments (1) | - | 4,228 | - | 4,228 | ||||
| Segment EBITDA adjustments (2) | - | - | 24 | - | ||||
| Segment adjusted EBITDA | 7,681 | 11,181 | 42,784 | 41,530 |
(1) Impairments represent the impairment of goodwill and intangible assets of Materialise Motion (3,572 kEUR) and the impairment of tangible and intangible assets of Engimplan (656 kEUR).
(2) Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of Feops.